HannahBlake, Author at

Articles/ Market Access/ Oncology/ R&D/ Sales and Marketing/ Views & Analysis/ Views & Analysis/ Views & Analysis/ Views & Analysis/ Views and analysis

A history of AstraZeneca

HannahBlake AstraZeneca 0 Comment

A look back at AstraZeneca and its roots in the UK and Sweden

A history of AstraZeneca

https://pharmaphorum.com/views-analysis-sales-marketing/a_history_of-_astrazeneca/

News

Sanofi’s Aubagio recommended for use on UK’s NHS

HannahBlake 0 Comment

The UK’s National Institute for Clinical and Health Excellence has issued final draft guidance recommending the NHS to

Sanofi’s Aubagio recommended for use on UK’s NHS

https://pharmaphorum.com/news/sanofis-aubagio-recommended-for-use-on-uks-nhs/

News

Phase 3 goal met by Novartis’ multiple myeloma drug

HannahBlake 0 Comment

Novartis’ investigational compound, LBH589, for multiple myeloma has met its primary endpoint in phase 3 clinical trials. LBH589

Phase 3 goal met by Novartis’ multiple myeloma drug

https://pharmaphorum.com/news/phase-3-goal-met-by-novartis-multiple-myeloma-drug/

News

Lilly’s depression drug fails to meet goal in phase 3

HannahBlake 0 Comment

Eli Lilly and Company’s edivoxetine did not meet its primary endpoint in phase 3 clinical trials as an

Lilly’s depression drug fails to meet goal in phase 3

https://pharmaphorum.com/news/lilly-s-depression-drug-fails-to-meet-goal-in-phase-3/

Articles/ Views and analysis

Digital health perspectives: Matt McNally

HannahBlake 0 Comment

Matt McNally, President of Publicis Health Media offers his insight into digital engagement in our latest ‘Digital health

Digital health perspectives: Matt McNally

https://pharmaphorum.com/views-and-analysis/digital-health-perspectives-matt-mcnally/

Cancer/ News

Roche, Molecular Partners in cancer deal worth over $1 billion

HannahBlake 0 Comment

Roche and Molecular Partners have entered into a research and licensing alliance to discover, develop and commercialize new

Roche, Molecular Partners in cancer deal worth over $1 billion

https://pharmaphorum.com/news/roche-molecular-partners-in-cancer-deal-worth-over-1-billion/

News

Sanofi reports positive phase 3 insulin data

HannahBlake 0 Comment

Full results from Sanofi’s phase three clinical trials of its investigational new insulin U300 have been announced. The

Sanofi reports positive phase 3 insulin data

https://pharmaphorum.com/news/sanofi-reports-positive-phase-3-insulin-data/

Articles/ Views and analysis

Defects and the development risk defence – an Australian perspective

HannahBlake 0 Comment

Mabel Tsui provides us with an Australian perspective on the development risk defence against a pharmaceutical product liability

Defects and the development risk defence – an Australian perspective

https://pharmaphorum.com/views-and-analysis/defects-and-the-development-risk-defence-an-australian-perspective/

Cancer/ News

Celgene, OncoMed sign $155m cancer deal

HannahBlake 0 Comment

OncoMed Pharmaceuticals and Celgene Corporation have signed an agreement to jointly develop and commercialize up to six anti-cancer

Celgene, OncoMed sign $155m cancer deal

https://pharmaphorum.com/news/celgene-oncomed-sign-155m-cancer-deal/

Trending

About HannahBlake

Posts by HannahBlake :

A history of AstraZeneca

Sanofi’s Aubagio recommended for use on UK’s NHS

Phase 3 goal met by Novartis’ multiple myeloma drug

Lilly’s depression drug fails to meet goal in phase 3

Digital health perspectives: Matt McNally

Roche, Molecular Partners in cancer deal worth over $1 billion

Sanofi reports positive phase 3 insulin data

Defects and the development risk defence – an Australian perspective

Celgene, OncoMed sign $155m cancer deal

Trending

About HannahBlake

Posts by HannahBlake :

Login